A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma

Summary

This is Phase I, open label, multi-center clinical trial evaluating an investigational treatment, Adze1.C. Adze1.C is a type of oncolytic virus therapy for adults with advanced Melanoma that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight tumors. The purpose of this study is to assess preliminary efficacy, determine the safety of Adze1.C, how well it is tolerated, and to identify the highest dose that can be safely given.

Timeline

Start

2025-10-01

Primary completion

2027-10-01

Completion

2028-10-01

Drugs

Indications